EIF2A and cancer: In contrast with these data, ricin and the RIP riproximin were recently reported to inhibit eIF2-α phosphorylation and to decrease intact ATF-6 protein in two human cancer cell lines, MCF-7 and HCT-11, indicating that these two UPR pathways were induced by toxin treatment [22].